MetaCap

DBV Technologies S.A. ADR Company Profile

NASDAQ: DBVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

9.02-0.40 (-4.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DBV Technologies S.A. at a glance

DBV Technologies S.A. ADR (NASDAQ: DBVT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Châtillon, France. DBV Technologies S.A. is led by Mr. Daniel Tassé and employs about 179 people. The company's shares have traded publicly since 2014.

At a market capitalization of $566.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001613780, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does DBV Technologies S.A. do?

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Business description based on the company's public filings.

Company information

Legal name
DBV Technologies S.A. ADR
Ticker
NASDAQ: DBVT
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Daniel Tassé
Employees
179
Headquarters
BAtiment IRO, Châtillon, France
Phone
33 1 55 42 78 78
IPO year
2014
Market cap
$566.82M
SEC CIK
0001613780
Latest annual report
10-K/A · Apr 30, 2026

Companies similar to DBV Technologies S.A.

DBVT peer companies
CompanyPrice% ChgMarket capCompare
ENTXEntera Bio Ltd.3.31+0.76%$575.53Mvs DBVT
FDMT4D Molecular Therapeutics Inc.10.23-4.57%$576.76Mvs DBVT
CGEMCullinan Therapeutics Inc.8.89-1.98%$577.15Mvs DBVT
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs DBVT
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs DBVT
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs DBVT
VALNValneva SE ADR5.16-3.82%$490.86Mvs DBVT
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs DBVT

Related